NICE IDs

14/05/2026

ID6195: Risdiplam for treating spinal muscular atrophy (review of TA755)

14/05/2026

ID6195: Nusinersen for treating spinal muscular atrophy (review of TA588)

13/05/2026

ID6578: Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis

08/05/2026

ID6163: Sotatercept for treating pulmonary arterial hypertension

01/05/2026

ID6619: Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987)

29/04/2026

ID6223: Osimertinib for maintenance treatment of EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy

29/04/2026

ID6323: Givinostat for treating Duchenne muscular dystrophy in people 6 years and over

27/04/2026

ID3753: Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment

27/04/2026

ID6374: Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer

22/04/2026

ID1237: Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

22/04/2026

ID5092: Rozanolixizumab for treating antibody-positive generalised myasthenia gravis

14/04/2026

ID6388: Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment

10/04/2026

ID6177: Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer

01/04/2026

ID6407: Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over

31/03/2026

ID6496: Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (review of TA881)

25/03/2026

ID6441: Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

06/03/2026

ID6477: Pembrolizumab before surgery (neoadjuvant) then with radiotherapy after surgery (adjuvant) for newly diagnosed, resectable, locally advanced, squamous cell head and neck cancer

04/03/2026

ID5071: Fezolinetant for treating vasomotor symptoms associated with the menopause

02/03/2026

ID6474: Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment

02/02/2026

ID6168: Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer